Arcturus Therapeutics is trading 5.1% up now at $16.23, driven primarily by anticipation of clinical data from its experimental mRNA rare-disease programs.
- Dosing is complete in the ARCT-810 Phase 2 study; data and the regulatory plan are expected later in the third quarter.
- Broader biotechnology strength is providing additional support, while shares have risen from $8.14 on August 17.